This chiral compound, an (R)-enantiomer of 1-(4-(trifluoromethyl)phenyl)propan-1-amine hydrochloride, is utilized in pharmaceutical research and development, particularly for studying central nervous system effects. As an amphetamine derivative, it modulates monoamine neurotransmitters such as serotonin and dopamine, aiding investigations into psychoactive properties, mood disorders like depression and anxiety, and related psychiatric conditions. The trifluoromethyl group improves its metabolic stability, supporting pharmacokinetic studies. It is also employed in the synthesis of chiral intermediates for enantiomerically pure drug candidates.